BioCryst Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCRX research report →
Range $11 – $29
Price Chart
About the company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza.
- CEO
- Charles K. Gayer
- IPO
- 1994
- Employees
- 435
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on BCRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.86B
- P/E
- -5.56
- Fwd P/E
- 13.62
- PEG
- 0.00
- P/S
- 2.01
- P/B
- -4.82
- EV/EBITDA
- -9.33
- Div Yield
- 0.00%
- Gross Margin
- 25.28%
- Op Margin
- -30.10%
- Net Margin
- -37.41%
- ROE
- 94.36%
- ROIC
- -65.42%
Latest fiscal year · YoY change
- Revenue
- $874.84M+94.1%
- Gross Profit
- $855.76M+95.3%
- Op Income
- $340.99M
- Net Income
- $263.86M+396.9%
- EPS
- $1.26+393.0%
- OCF Growth
- +734.1%
- FCF Growth
- +716.1%
- 52W High
- $11.22
- 52W Low
- $6.23
- 50D MA
- $8.10
- 200D MA
- $8.82
- Beta
- 0.54
- RSI (14)
- 35
- Avg Volume
- 4.95M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioCryst posted strong Q3 execution and profitability, boosted by ORLADEYO growth, a one-time CareMed inventory build, and higher full-year revenue guidance.· November 4, 2026
- Q3 net revenue was $174.8 million, with >95% from the U.S.; ORLADEYO revenue excluding Europe rose 20% year over year.
- Non-GAAP operating profit was $86 million, up 70% year over year, and non-GAAP net income was $71 million, more than doubling from last year.
- The CareMed pharmacy transition created an upper-teens-of-millions revenue benefit from inventory build, but management said it is one-time and revenue should more closely track demand going forward.
- ORLADEYO pediatric pellet launch is outperforming expectations, with 47 pediatric patients previously disclosed and management saying the market may prove larger than the 500-patient estimate.
- Full-year 2026 revenue guidance was raised to $715 million to $730 million, while ORLADEYO guidance stayed at $625 million to $645 million and operating expense guidance was tightened to $415 million to $425 million.
BioCryst reported Q3 net revenue of $174.8 million, with more than 95% from the U.S. On a comparable basis excluding European revenue, ORLADEYO revenue increased 20% year over year. The CareMed transition added an upper-teens-of-millions revenue contribution in the quarter from inventory build. Non-GAAP operating profit was $86 million, up 70% year over year, and non-GAAP net income was $71 million, more than double the prior-year period. Cash and equivalents were $376 million. For 2026, management raised total revenue guidance to $715 million to $730 million, reflecting higher realized licensing revenue and international RAPIVAB orders. ORLADEYO revenue guidance was unchanged at $625 million to $645 million because management said it did not want to bake in a temporary inventory effect. Full-year non-GAAP operating expense guidance was lowered to $415 million to $425 million. Management also said 2026 actions are expected to generate approximately $30 million to $35 million of annualized savings once fully realized.
Charles K. Gayer emphasized that the quarter reflected strong execution during a strategic transition, with ORLADEYO continuing to show strong prescription trends and new pediatric pellets off to a promising start. He said the pediatric opportunity may grow beyond the previously discussed 500 patients and noted that the newly approved 150 mg pellet formulation could broaden use across kids, adolescents, and adults. He also highlighted navenibart, saying the pivotal trial remains on track for top-line 12-month data in the third quarter of next year, and framed the company’s shift toward external innovation as a deliberate step supported by profitability, discipline, and execution.
Babar Ghias focused on the improving financial profile: Q3 revenue of $174.8 million, non-GAAP operating profit of $86 million, non-GAAP net income of $71 million, and cash of $376 million. He said the Birmingham closure and restructuring remain on track to be substantially completed by year-end, with about $19 million of restructuring-related expenses in the quarter, of which only $10 million were cash costs. He also said the cost actions should deliver roughly $30 million to $35 million of annualized savings, and that 2027 should bring lower operating expenses alongside continued revenue growth. On guidance, he raised total revenue but left ORLADEYO guidance unchanged because the CareMed inventory build is temporary and should not be treated as recurring demand.
Analysts focused heavily on the CareMed pharmacy transition, asking whether the upper-teens million inventory benefit would reverse next quarter and why management did not raise ORLADEYO guidance. Management said the inventory build was a one-time effect, that CareMed typically holds only about 7 to 21 days of inventory, and that guidance should reflect patient demand rather than a temporary stocking dynamic. Questions also centered on pediatrics, where management said demand is running ahead of expectations, additions have been steady after an initial bolus, and 47 pediatric patients had already been disclosed previously. On the pipeline, management said the Netherton program will be judged by the totality of data, with 20% to 25% improvement in the primary IASI score described as a meaningful benchmark, but they were not committing to an immediate pivotal move without reviewing the full readout.
The call showed a business with strong commercial momentum and improving economics: ORLADEYO grew 20% year over year excluding Europe, pediatrics is tracking ahead of initial expectations, and the company is seeing higher profitability with lower operating expenses. Management also sounded confident about 2027, citing new cost savings, pipeline catalysts, and the possibility that navenibart could expand the HAE franchise with both 3- and 6-month dosing options.
Near-term ORLADEYO revenue is being distorted by a one-time pharmacy inventory build, and management would not raise ORLADEYO guidance until the new CareMed model normalizes. The company also flagged that pediatrics is still early, Netherton data are not yet in hand, and navenibart remains a future catalyst rather than current revenue, so a meaningful portion of the long-term story still depends on clinical execution and launch success.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.0%
- Shares Outstanding
- 257.30M
- Float Shares
- 221.18M
of shares held by institutions
335 13F filers
Congressional trading
Senate and House stock disclosures for BCRX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 24.33M | ▲ 441.42K |
| Vanguard Group Inc | 22.27M | ▲ 482.49K |
| Ra Capital Management, L.P. | 15.83M | 0 |
| Deerfield Management Company, L.P. | 15.10M | ▲ 58.40K |
| State Street Corp | 12.29M | ▼ 2.90M |
| Vanguard Capital Management LLC | 11.27M | ▼ 97.25K |
| Tcg Crossover Management, LLC | 11.02M | 0 |
| Vanguard Portfolio Management LLC | 10.53M | ▼ 605.83K |
| Perceptive Advisors LLC | 10.31M | ▲ 2.87M |
| Jupiter Topco LLC | 9.54M | ▲ 9.54M |
| Janus Henderson Group Ltd. | 8.91M | ▲ 1.50M |
| Vestal Point Capital, LP | 8.30M | ▲ 1.27M |
Held by 361 ETFs
Biggest fund positions in BCRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 26 | Stonehouse Jon P | other | 644 |
| Aug 31, 26 | Milne Jill C. | other | 1,288 |
| Aug 31, 26 | MILANO VINCENT | other | 1,159 |
| Aug 31, 26 | McKee Amy E | other | 644 |
| Aug 31, 26 | Frank Steven | other | 1,288 |
| Jun 11, 26 | Milne Jill C. | other | 33,540 |
| Jun 11, 26 | Milne Jill C. | other | 15,294 |
| Jun 11, 26 | Galson Steven K | other | 33,540 |
| Jun 11, 26 | Galson Steven K | other | 15,294 |
| Jun 11, 26 | LEVIN ALAN G | other | 15,294 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCRX coverage
Recent articles, reports, and earnings notes.

Latigo Biotherapeutics IPO: The Bull and Bear Case
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) is expected to list on 2026-08-07 at a price range of $16.00 to $18.00 per share. The company is offering 16,000,000 shares, with a disclosed market cap of $331.2 million. The bull case is a differentiated non-opioid pain platform; the bear case is a clinical-stage biotech with no revenue, rising losses, and a long road to approval.

Best Biotech Stocks for September 2026: 7 Research Candidates
A seven-stock biotech countdown spans rare-disease developers, CNS specialists, platform collaborations and commercial-stage therapeutic franchises.
Want a deeper read on BCRX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
marketbeat.com · Nov 20
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
globenewswire.com · Nov 13
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
zacks.com · Nov 10
Head-To-Head Review: BioCryst Pharmaceuticals (NASDAQ:BCRX) & Zenas BioPharma (NASDAQ:ZBIO)
defenseworld.net · Nov 5
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
seekingalpha.com · Nov 4
BioCryst Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 4
BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.